TGFB1 and neoplasm: In conclusion, the studies presented here demonstrate that dual targeting of PD-1/PD-L1 and TGFβ immunosuppressive pathways with the novel bifunctional agent M7824 promotes potent anti-tumor responses in murine models of human solid carcinomas.